- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06283615
Effect of Vitamin D on Skeletal Muscle Function and Qol in Patients With Chronic Intestinal Failure/Insufficiency
Effect of Vitamin D Supplementation on Skeletal Muscle Function and Quality of Life in Patients With Chronic Intestinal Failure/Insufficiency: A Randomised Clinical Trial
Eligible patients were randomized into two groups: Vitamin D group and Control group. Control group: routine treatment only, no additional vitamin D intervention therapy. Vitamin D group: In addition to the conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks.
The primary and secondary outcomes will be collected.
Study Overview
Detailed Description
Eligible patients with chronic intestinal failure/insufficiency were randomly assigned to one of two groups, Vitamin D group and Control group. Control group: routine treatment only, no additional vitamin D intervention therapy. Vitamin D group: In addition to the conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks.
The primary and secondary outcomes will be collected.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Xuejin Gao, MD
- Phone Number: +86 18251937684
- Email: 547625433@qq.com
Study Contact Backup
- Name: Xinying Wang, MD
- Phone Number: +86 13913028866
- Email: wangxinying@nju.edu.cn
Study Locations
-
-
Jiangsu
-
Nanning, Jiangsu, China, 210002
- Recruiting
- Xinying Wang
-
Contact:
- Xuejin Gao, MD
- Phone Number: +86 18251937684
- Email: 547625433@qq.com
-
Contact:
- Xinying Wang, MD
- Phone Number: +86 13913028866
- Email: wangxinying@nju.edu.cn
-
Principal Investigator:
- Xinying Wang, MD
-
Sub-Investigator:
- Xuejin Gao, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Informed consent was obtained from patients or their legal representatives for participation in this study
- Patients 18 years of age or older, under 70 years of age, chronic intestinal failure/insufficiency
- Serum 25(OH)D level < 30.0 ng/ml
- Vital signs are stable
Exclusion Criteria:
- Those who did not meet the inclusion criteria, or who were deemed unfit by their physician to participate in this study
- Primary hypothyroidism or parathyroidism
- Patients suffering from allergic diseases, are allergic, have a history of drug sensitivity similar to the structure of the study drug
- Patients with primary diabetes
- Patients with mental illness, inability to cooperate or consciousness disorders
- Patients with contraindications of experimental drugs
- Patients with a suspected or confirmed history of substance abuse
- Immune deficiency, use of immunosuppressants and hormones
- Pregnant and lactating women
- Have taken any vitamin D supplements in the last 6 months
- Have taken any medication in the last 6 months that affects vitamin D metabolism (e.g., phenytoin, phenobarbital, rifampicin)
- Patients who participated in a drug trial (including the drug in the trial) within 3 months before the trial
- Sponsors or investigators directly involved in the trial or their family members
- The researcher believes that there is any reason not to be accepted
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vitamin D
Experimental group: In addition to conventional treatment, additional intramuscular injection of vitamin D2 was given once every two weeks, each dose of 600,000 units, and the treatment lasted for 12 weeks.
|
Vitamin D2 injection
Other Names:
|
No Intervention: Control
Control group: routine treatment only, no additional vitamin D intervention therapy.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Quality of life score
Time Frame: up to 12 weeks
|
Quality of life was assessed using the SF-36 score from the date of randomization until the end of the 12-week intervention weeks.
SF-36 consists of eight dimensions, each of which is measured on a scale of 0-100, with higher scores indicating a better quality of life.
|
up to 12 weeks
|
Muscle function status
Time Frame: up to 12 weeks
|
Including hand grip strength(kg); Appendicular skeletal muscle mass index (ASMI) = limb muscle mass (kg)/height (m)2;6 meters walking speed(m/s)
|
up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Serum vitamin D levels
Time Frame: up to 12 weeks
|
Serum 25 hydroxyvitamin D levels
|
up to 12 weeks
|
Hepatic and renal function
Time Frame: up to 12 weeks
|
Liver function includes the following indicators: Alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBil), direct and indirect bilirubin, γ-glutamyltranspeptidase (γ-GT) and alkaline phosphatase (ALP).
Kidney function includes the following indicators: serum creatinine and blood urea nitrogen.
|
up to 12 weeks
|
Bone mineral density
Time Frame: up to 12 weeks
|
Bone mineral density by DXA
|
up to 12 weeks
|
Thyroid and parathyroid-related hormones
Time Frame: up to 12 weeks
|
Including surum total triiodothyroxine, total tetraiodothyroxine, free triiodothyronine, free tetraiodothyroxine, thyroid stimulating hormone, parathyroid hormone and calcitonin.
|
up to 12 weeks
|
Nutritional status indicators
Time Frame: up to 12 weeks
|
Including body weight (kg), serum albumin (g/L) and prealbumin (mg/L) levels.
|
up to 12 weeks
|
Number of participants with treatment-related adverse events
Time Frame: up to 12 weeks
|
Occurrence of hypercalcemia and hyperphosphatemia during intervention and follow-up. The blood calcium concentration > 2.75 mmol/L is called hypercalcemia. Normal human blood phosphorus concentration is relatively stable (normal reference value 0.87~1.45mmol/ L), when the determination result is greater than the normal reference value of 1.45mmol/ L, it can be diagnosed as hyperphosphatemia. Occurrences of kidney stones during intervention and follow-up. Kidney stones are examined by ultrasound. Incidence of fall-related fractures during intervention and follow-up. |
up to 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Xinying Wang, MD, Jinling Hospital, China
Publications and helpful links
General Publications
- Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1678S-88S. doi: 10.1093/ajcn/80.6.1678S.
- Pironi L, Corcos O, Forbes A, Holst M, Joly F, Jonkers C, Klek S, Lal S, Blaser AR, Rollins KE, Sasdelli AS, Shaffer J, Van Gossum A, Wanten G, Zanfi C, Lobo DN; ESPEN Acute and Chronic Intestinal Failure Special Interest Groups. Intestinal failure in adults: Recommendations from the ESPEN expert groups. Clin Nutr. 2018 Dec;37(6 Pt A):1798-1809. doi: 10.1016/j.clnu.2018.07.036. Epub 2018 Aug 18.
- Khan FA, Fisher JG, Bairdain S, Sparks EA, Zurakowski D, Modi BP, Duggan C, Jaksic T. Metabolic bone disease in pediatric intestinal failure patients: prevalence and risk factors. J Pediatr Surg. 2015 Jan;50(1):136-9. doi: 10.1016/j.jpedsurg.2014.10.010. Epub 2014 Oct 17.
- Yang CF, Duro D, Zurakowski D, Lee M, Jaksic T, Duggan C. High prevalence of multiple micronutrient deficiencies in children with intestinal failure: a longitudinal study. J Pediatr. 2011 Jul;159(1):39-44.e1. doi: 10.1016/j.jpeds.2010.12.049. Epub 2011 Feb 16.
- Reid IR, Bolland MJ, Grey A. Effects of vitamin D supplements on bone mineral density: a systematic review and meta-analysis. Lancet. 2014 Jan 11;383(9912):146-55. doi: 10.1016/S0140-6736(13)61647-5. Epub 2013 Oct 11.
- Lepus CA, Samela K, Emerick KM, Mokha JS. Vitamin D status in children with intestinal failure who have achieved enteral autonomy. Nutr Clin Pract. 2021 Dec;36(6):1284-1289. doi: 10.1002/ncp.10685. Epub 2021 Jun 23.
- Wozniak LJ, Bechtold HM, Reyen LE, Hall TR, Vargas JH. Vitamin D deficiency in children with intestinal failure receiving home parenteral nutrition. JPEN J Parenter Enteral Nutr. 2015 May;39(4):471-5. doi: 10.1177/0148607114527135. Epub 2014 Mar 14.
- Allan PJ, Lal S. Metabolic bone diseases in intestinal failure. J Hum Nutr Diet. 2020 Jun;33(3):423-430. doi: 10.1111/jhn.12726. Epub 2019 Dec 11.
- Diamanti A, Capriati T, Cardile S, Benedetti S, Francalanci P, Elia D. Fat-soluble vitamin deficiency in children with intestinal failure receiving home parenteral nutrition. J Pediatr Gastroenterol Nutr. 2014 Nov;59(5):e46. doi: 10.1097/MPG.0000000000000508. No abstract available.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2024-01-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intestinal Failure
-
SterileCare Inc.Not yet recruitingPediatric Intestinal Failure
-
University Hospital, BordeauxCompletedChronic Intestinal FailureFrance
-
Instituto Nacional de Ciencias Medicas y Nutricion...CompletedIntestinal FailureMexico
-
Geert WantenBaxter Healthcare CorporationCompletedIntestinal FailureNetherlands
-
University Hospital, GhentCompleted
-
NorthSea Therapeutics B.V.RecruitingIntestinal Failure Associated Liver DiseaseUnited States
-
Seattle Children's HospitalNational Center for Research Resources (NCRR); Thrasher Research FundCompletedIntestinal Failure | Rotavirus VaccinesUnited States
-
University of PittsburghCompletedAllograft Rejection | Irreversible Intestinal FailureUnited States
-
Protara TherapeuticsCompletedIntestinal Failure-associated Liver DiseaseUnited States, Denmark, United Kingdom, Italy
-
Children's Hospital Medical Center, CincinnatiEnrolling by invitation
Clinical Trials on Vitamin D
-
PfizerTerminated
-
Umeå UniversityRegion SkaneCompleted
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SACompletedVitamin D Deficiency | Overweight and Obesity | Overweight AdolescentsColombia
-
Khon Kaen UniversityNot yet recruiting
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens Int...CompletedVitamin D DeficiencySlovenia
-
USDA, Western Human Nutrition Research CenterCompletedVitamin D DeficiencyUnited States
-
University of AarhusNot yet recruitingImmune System Diseases | Growth | Child Development | Vitamin D Supplementation
-
University Hospital, Basel, SwitzerlandCompleted
-
Cornell UniversityArogyavaram Medical CentreNot yet recruiting
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting